Inflammation control by promyelocytic leukaemia protein
Promyelocytic leukaemia protein (PML) is is a tumour suppressor protein required for the assembly of nuclear structures, called PML-nuclear bodies, which are formed amongst the chromatin of the cell nucleus. PML mutations and the subsequent dysregulation has been implicated in a variety of cancers. The EU-funded InflaPML project proposes that several neuroinflammatory diseases can be linked through a common molecular pathway, whose molecular components could be targeted for therapy. Researchers propose a new mechanism involving IL-1β regulation. Specifically, they hypothesise that PML has an additional role outside the tumour environment, acting at the endoplasmic reticulum-mitochondria interfaces as a modulator of NLRP3, or cryopyrin, a protein expressed in macrophages as a component of the inflammasome. The ultimate goal of the project is to develop drugs targeting a PML-associated pathway for treatment of neuroinflammatory diseases.
Fields of science
Call for proposalSee other projects for this call
Funding SchemeERC-STG - Starting Grant
See on map
See on map